权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Endonuclease-mediated disruption of latent HSV as curative therapy

核酸内切酶介导的潜伏 HSV 破坏作为治疗方法

基本信息

批准号：
9927580
负责人：
KEITH R JEROME
金额：
$ 43.78万
依托单位：
FRED HUTCHINSON CANCER RESEARCH CENTER
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-06-12 至 2023-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9927580
关键词：
Address Afferent Neurons Animal Model Animals Antiviral Agents Antiviral Therapy Area Autonomic ganglion CRISPR/Cas technology Cell Death Cells Chronic Clinic Clinical DNA DNA Integration Data Dependovirus Development Disease Enzymes Evaluation Excision Frequencies Ganglia Gene Delivery Genes Genome Genomics Goals HIV Health behavior Hepatitis B Virus Herpesvirus Type 3 Homing Human Genome Human Papillomavirus Immunochemistry Individual Infiltration Inflammatory Injections Kinetics Laboratories Latent virus infection phase Lead Measures Mediating Morbidity - disease rate Mus Mutagenesis Mutate Mutation Neurons Pathway interactions Phenotype Primary Infection Process Recurrence Recurrent disease Reporter Reproducibility Route Safety Sampling Sensory Ganglia Serotyping Shock Simplexvirus Site Source Staphylococcus aureus System Technology Testing Therapeutic Therapeutic Effect Time Treatment Efficacy Vaccines Vibrissae Viral Viral Genome Viral Load result Viral Pathogenesis Viral reservoir Virus Virus Diseases Virus Integration Virus Latency Virus Replication Work clinical application clinical development curative treatments endonuclease genome-wide analysis genotoxicity improved in vivo innovation insertion/deletion mutation mouse genome mouse model next generation sequencing novel therapeutic intervention nuclease preclinical development promoter reactivation from latency screening targeted nucleases therapeutic development transgene delivery transgene expression transmission process vector viral DNA virology

项目摘要

Project Summary Herpes simplex virus (HSV) infections remain a common, serious problem associated with significant morbidity. After primary infection, HSV establishes latency, which is not eliminated by current antiviral therapy. Latent virus is the source for viral reactivation and the recurrence of clinical disease. Despite much effort, a vaccine remains elusive. Therefore, there is a need for a novel therapeutic approach that would cure latent HSV infection. We have been developing a new curative strategy to latent HSV infection, in which an HSV-targeted endonuclease induces mutagenesis of essential HSV genes, disabling viral genomes and rendering the virus incapable of replication or reactivation from latency. Our hypothesis is that recent advances in the field of gene-editing technologies and in vivo gene delivery offer the opportunity to improve our current anti-viral approach and reach therapeutic efficacy. Here, we propose to evaluate Staphylococcus aureus (Sa)CRIPSR/Cas9 and homing endonucleases (HEs) for their ability to disable HSV in latently infected neurons by targeted viral genome disruption, thus eliminating the source of viral pathogenesis in an animal model of HSV infection. The goal of this project is to maximize the efficacy and safety of our approach to eliminate latent HSV infection in vivo, using a murine model of HSV latent infection. Our results will also be applicable in efforts to cure varicella zoster virus, another alphaherpesvirus that like HSV establishes latency in sensory neurons. Furthermore, the data generated will be highly relevant to the development of cures for other chronic or latent viral infections such as hepatitis B virus, HIV, or human papillomavirus. In SA1: Address the remaining barriers to effective in vivo HSV gene editing, we will compare 1) new AAV serotypes to our current AAV serotypes for transgene delivery after administration via different routes, and 2) the gene editing abilities of CRISPR/Cas9 vs. HEs. In SA2: Optimize the efficacy of in vivo gene editing and determine the impact on viral pathogenesis, we will evaluate whether the simultaneous targeting of two HSV sites provides superior efficacy over targeting a single site, and the efficacy of gene editing necessary to impact viral pathogenesis. In SA3: Evaluate the safety of in vivo gene editing in our mouse model, we will use our mouse model of latent HSV infection to evaluate tolerability, safety, and genotoxicity of nuclease exposure. This project is expected to demonstrate the feasibility of our therapeutic approach directed towards the elimination of HSV pathogenesis in vivo, and to provide critical information for the development of a larger scale animal study necessary to bring this new therapeutic approach to the clinic.

项目摘要单纯疱疹病毒（HSV）感染仍然是一种常见的、严重的问题，与严重的发病率初次感染后，HSV建立潜伏期，目前的抗病毒治疗无法消除。潜伏病毒是病毒再激活和临床疾病复发的根源。尽管付出了很多努力，A 疫苗仍然难以捉摸。因此，需要一种新的治疗方法，潜伏性HSV感染。我们一直在开发一种新的治疗策略来治疗潜伏性HSV感染， HSV-靶向核酸内切酶诱导必需HSV基因的诱变，使病毒基因组失能，使病毒不能复制或从潜伏期重新激活。我们的假设是最近的进展在基因编辑技术和体内基因递送领域，抗病毒途径，达到治疗效果。在这里，我们建议评估金黄色葡萄球菌（Sa）CRIPSR/Cas9和归巢核酸内切酶（HE）在潜伏感染的HSV中使HSV失能的能力，通过靶向病毒基因组破坏神经元，从而消除动物中病毒发病的来源 HSV感染模型。该项目的目标是最大限度地提高我们的方法的有效性和安全性，使用HSV潜伏感染的鼠模型消除体内潜伏HSV感染。我们的结果也将是可用于治疗水痘带状疱疹病毒，另一种α疱疹病毒，如HSV建立潜伏期，感觉神经元此外，所产生的数据将与其他疾病的治疗方法的发展高度相关。慢性或潜伏性病毒感染，如B型肝炎病毒、HIV或人乳头瘤病毒。在SA 1中：解决有效体内HSV基因编辑的剩余障碍，我们将比较1）新的 AAV血清型与我们目前的AAV血清型在通过不同途径施用后用于转基因递送，和2）CRISPR/Cas9相对于HE的基因编辑能力。在SA 2中：优化体内基因的功效编辑和确定对病毒发病机制的影响，我们将评估是否同时两个HSV位点的靶向提供了优于靶向单个位点的上级功效，并且基因治疗的功效与靶向单个位点的功效相同。编辑影响病毒发病机制所必需的。在SA 3中：评估我们的体内基因编辑的安全性小鼠模型，我们将使用我们的潜伏性HSV感染的小鼠模型来评估耐受性、安全性和核酸酶暴露的遗传毒性。该项目有望证明我们的治疗方法的可行性，消除体内HSV发病机制，并为开发更大的将这种新的治疗方法引入临床所需的大规模动物研究。